Watson buys Greek generic maker Specifar

Home/Pharma News | Posted 10/06/2011 post-comment0 Post your comment

Watson Pharmaceuticals announced on 25 May 2011 that it had bought the Greece-based generic manufacturer Specifar Pharmaceuticals for Euros 400 million with the intention of increasing its generics presence in Europe.

picture41

The move expands US-based Watson’s presence in Europe, after its 2009 acquisition of the Arrow group, as well as giving the company a presence in the Euros 6 billion Greek generics market.

The Specifar is in the top five in the Greek branded-generic market, with a portfolio of more than 30 products, including a non-branded version of AstraZeneca’s blockbuster anti-reflux drug Nexium (esomeprazole), which could be launched in Europe in the fourth quarter of 2011.

Specifar currently manufactures generic drugs in an EU-approved facility in Athens with capacity for approximately one billion doses annually. A new plant is currently being built just outside Athens, which will manufacture an additional three to five billion doses. This capacity will ultimately permit Watson to convert additional third-party manufactured products to own-manufactured.

Greece’s use of generics is currently one of the lowest in Europe, providing Watson with a significant opportunity to capitalise on growth in this market.

Source: Watson Pharmaceuticals

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010